The impact of comorbidity on the survival of postmenopausal women with breast cancer

被引:47
作者
Nagel, G
Wedding, U
Hoyer, H
Röhrig, B
Katenkamp, D
机构
[1] Deutsch Krebsforschungszentrum, Div Clin Epidemiol, D-69120 Heidelberg, Germany
[2] Univ Jena, Ctr Comprehens Canc, Field Study Breast Canc, D-6900 Jena, Germany
[3] Univ Jena, Clin Internal Med 2, D-6900 Jena, Germany
[4] Univ Jena, Inst Med Stat Comp Sci & Documentat, D-6900 Jena, Germany
关键词
breast cancer; comorbidity; survival;
D O I
10.1007/s00432-004-0594-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim was to assess the impact of comorbidity on survival of postmenopausal women with breast cancer diagnosis in the period 1995-1997. Methods: The level of comorbidity was described by the methods suggested by Satariano and Charlson. Cox's proportional hazard models were used to explore the impact of comorbidity on all-cause mortality. Results: After a median follow-up time of 52 months, an increasing level of comorbidity was associated with a higher all-cause mortality. Compared to patients without comorbid conditions, the hazard ratio of death (HR) was 1.2 (95% Cl: 0.8-1.7) for Satariano index 1 and HR 2.3 (95% Cl: 1.5-3.5) for Satariano index greater than or equal to2, and HR 1.6 and 2.1 for the Charlson comorbidity index, respectively. Independent of comorbidity, the treatment pattern had a strong impact on survival. The level of comorbidity has an influence on the 3-year survival of postmenopausal women with breast cancer. Conclusions: Long-term follow-up is required to appraise these findings in relation to treatment strategies.
引用
收藏
页码:664 / 670
页数:7
相关论文
共 42 条
[31]   THE EFFECT OF COMORBIDITY ON 3-YEAR SURVIVAL OF WOMEN WITH PRIMARY BREAST-CANCER [J].
SATARIANO, WA ;
RAGLAND, DR .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (02) :104-110
[32]  
SILLIMAN RA, 1997, CANCER, V20, P1326
[33]   Impact of comorbidity on lung cancer survival [J].
Tammemagi, CM ;
Neslund-Dudas, C ;
Simoff, M ;
Kvale, P .
INTERNATIONAL JOURNAL OF CANCER, 2003, 103 (06) :792-802
[34]   STAGE, AGE, COMORBIDITY, AND DIRECT COSTS OF COLON, PROSTATE, AND BREAST-CANCER CARE [J].
TAPLIN, SH ;
BARLOW, W ;
URBAN, N ;
MANDELSON, MT ;
TIMLIN, DJ ;
ICHIKAWA, L ;
NEFCY, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (06) :417-426
[35]  
Terry PD, 2002, CANCER EPIDEM BIOMAR, V11, P953
[36]  
*UICC, 1997, TNM CLASS MAL TUM
[37]   Limiting comorbid conditions and breast cancer stage at diagnosis [J].
Vaeth, PAC ;
Satariano, WA ;
Ragland, DR .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2000, 55 (10) :M593-M600
[38]   Multimorbidity in general practice: Prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases [J].
van den Akker, M ;
Buntinx, F ;
Metsemakers, JFM ;
Roos, S ;
Knottnerus, JA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (05) :367-375
[39]   Cancer and comorbidity in older patients: A descriptive profile [J].
Yancik, R ;
Havlik, RJ ;
Wesley, MN ;
Ries, L ;
Long, S ;
Rossi, WK ;
Edwards, BK .
ANNALS OF EPIDEMIOLOGY, 1996, 6 (05) :399-412
[40]  
Yancik R, 1998, CANCER, V82, P2123, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2123::AID-CNCR6>3.0.CO